Hong Kong Electrical Stock News

SEHK:9969
SEHK:9969Biotechs

A Look At InnoCare Pharma (SEHK:9969) Valuation As It Targets First Profit On 2025 Revenue Growth

InnoCare Pharma (SEHK:9969) is back in focus after the company projected an improvement in its 2025 financial performance, supported by stronger drug sales and an anticipated move into profitability for the first time. See our latest analysis for InnoCare Pharma. That profit outlook comes after a mixed share price run, with the latest close at HK$11.72. The 1 year total shareholder return of 111.93% contrasts with a 5 year total shareholder return decline of 44.06%. This suggests recent...
SEHK:9863
SEHK:9863Auto

A Look At Leapmotor (SEHK:9863) Valuation After Clarifying Independent Domestic Share Subscription

Zhejiang Leapmotor Technology (SEHK:9863) has detailed a domestic share subscription under its general mandate, highlighting state owned Jinyi High-Tech as an independent, non connected investor and stressing compliance with Hong Kong listing rules. See our latest analysis for Zhejiang Leapmotor Technology. At a latest share price of HK$42.42, Zhejiang Leapmotor Technology’s short term share price returns, including a 30 day share price return of a 14.41% decline and a 90 day share price...
SEHK:1729
SEHK:1729Electrical

Assessing Time Interconnect Technology (SEHK:1729) Valuation After New Board And MedTech Leadership Appointments

Time Interconnect Technology (SEHK:1729) has reshaped its leadership with three new board appointments, bringing its Chief Operating Officer, its Executive Vice President for MedTech, and a healthcare academic leader formally into director roles. See our latest analysis for Time Interconnect Technology. The leadership reshuffle comes after a period of mixed share price momentum, with a 1 day share price return of 4.59% from a last close of HK$15.5, set against a 30 day share price return of...
SEHK:1672
SEHK:1672Biotechs

Assessing Ascletis Pharma (SEHK:1672) Valuation After Positive Acne Data And Denifanstat NDA Acceptance

Ascletis Pharma (SEHK:1672) is back in focus after reporting favorable long term safety data from its Phase III acne drug denifanstat and confirming that China’s regulator has accepted its New Drug Application. See our latest analysis for Ascletis Pharma. The acne data and NDA progress come on the back of an active few weeks across its GLP 1 and metabolic pipeline. The share price has moved accordingly, with a 30 day share price return of 19.79% and 90 day share price return of 40.67%, adding...
SEHK:9899
SEHK:9899Entertainment

A Look At NetEase Cloud Music SEHK 9899 Valuation After Recent Share Price Volatility

Recent share performance and business snapshot NetEase Cloud Music (SEHK:9899) has seen a mix of short term moves, with a 1 day decline of 2.3% contrasting with a small gain over the past week and weaker returns over the past month and past 3 months. At a last close of HK$180.50, the company reports annual revenue of HK$7,706.77 and net income of HK$2,637.17, alongside positive annual revenue and net income growth figures. See our latest analysis for NetEase Cloud Music. Looking beyond the...
SEHK:656
SEHK:656Industrials

Is Fosun International (SEHK:656) Offering Value After Prolonged Share Price Declines

If you are wondering whether Fosun International's share price reflects its underlying value, you are not alone. This article is designed to help you frame that question clearly. The stock last closed at HK$4.16, with returns of 0.2% over 7 days, a 5.0% decline over 30 days, a 5.2% decline year to date, and a 1.7% decline over 1 year. The 3 year and 5 year returns show declines of 43.4% and 61.6% respectively. These price moves have put valuation back on many investors' radar, especially as...